This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
melanoma
Melanoma
Skin cancer from melanocytes; BRAF V600E (50%) and NRAS Q61 (25%) are dominant drivers. Dual checkpoint blockade (nivolumab + ipilimumab) and BRAF+MEK inhibitors (dabrafenib+trametinib) each achieve ~50-60% responses; 5-year OS ~50% in the immunotherapy era.
Entry Metadata
| Field | Value |
|---|---|
| ID | melanoma |
| Name | Melanoma |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34. · PubMed 26027431
- Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39. · PubMed 25399551
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127-137. · PubMed 34958258